Article: Home infusion with Elosulfase alpha (Vimizim
Molecular genetics and metabolism reports
2017 Volume 14, Page(s) 15–18
Abstract: Enzyme replacement therapy is the only available treatment for Mucopolysaccharidosis type IVA (MPS IVA, Morquio syndrome). The treatment is lengthy and invasive involving weekly intravenous infusions of 4-5 h. This can cause significant disruption to ... ...
| Abstract | Enzyme replacement therapy is the only available treatment for Mucopolysaccharidosis type IVA (MPS IVA, Morquio syndrome). The treatment is lengthy and invasive involving weekly intravenous infusions of 4-5 h. This can cause significant disruption to normal family life so the provision of a safe and effective homecare service is essential. In order to deliver a safe service, robust standards must be in place; this includes appropriately trained members of homecare staff, detailed management for infusion related reactions (IRR) and appropriate venous access. In this report we demonstrate the criteria required to ensure a successful home treatment programme and describe our experience thus far. |
|---|---|
| Language | English |
| Publishing date | 2017-11-05 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 2821908-9 |
| ISSN | 2214-4269 |
| ISSN | 2214-4269 |
| DOI | 10.1016/j.ymgmr.2017.10.012 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.